Detalhe da pesquisa
1.
Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial.
Blood
; 129(25): 3304-3313, 2017 06 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-28389462
2.
Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971.
Blood
; 118(26): 6752-9; quiz 6996, 2011 Dec 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-21849481
3.
Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group.
Cancer
; 118(19): 4806-14, 2012 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22392565
4.
Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial.
Blood
; 115(14): 2740-8, 2010 Apr 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-20124218
5.
Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions.
Mol Diagn Ther
; 17(1): 31-47, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23355100
6.
Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group.
Blood
; 108(4): 1165-73, 2006 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16609069